Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98(15):8554–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chirnomas D, Hornberger KR, Crews CW. Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20(4):265–78.

Article  CAS  PubMed  Google Scholar 

Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: The past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.

Article  PubMed  PubMed Central  Google Scholar 

Schneider M, Radoux CJ, Hercules A, Ochoa D, Dunham I, Zalmas LP, Hessler G, Ruf S, Shanmugasundaram V, Hann MM, Thomas PJ, Queisser MA, Benowitz AB, Brown K, Leach AR. The PROTACtable genome. Nat Rev Drug Discov. 2021;20(10):789–97.

Article  CAS  PubMed  Google Scholar 

Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol. 2020;27(8):998–1014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li K, Crews CM. PROTACs: Past, present and future. Chem Soc Rev. 2022;51(12):5214–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Zhi Y, Liu B, Yao Q. Advancing strategies for proteolysis-targeting chimera design. J Med Chem. 2023;66(4):2308–29.

Article  CAS  PubMed  Google Scholar 

Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem. 2021;225:113749.

Article  CAS  PubMed  Google Scholar 

Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181(1):102–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018;36:553–62.

Article  PubMed  PubMed Central  Google Scholar 

Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022;227:113906.

Article  CAS  PubMed  Google Scholar 

Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, Tong Y, Rao Y. PROTACs: Great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.

Article  PubMed  PubMed Central  Google Scholar 

He M, Cao C, Ni Z, Liu Y, Song P, Hao S, He Y, Sun X, Rao Y. PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7(1):181.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mullard A. Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021;20(4):247–50.

Article  CAS  PubMed  Google Scholar 

Garber K. The PROTAC gold rush. Nat Biotechnol. 2022;40(1):12–6.

Article  CAS  PubMed  Google Scholar 

Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10(2):207–38.

Article  CAS  PubMed  Google Scholar 

Kong NR, Jones LH. Clinical translation of targeted protein degraders. Clin Pharmacol Ther. 2023;114(3):558–68.

Article  CAS  PubMed  Google Scholar 

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten WI, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Churcher I. Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones? J Med Chem. 2018;61(2):444–52.

Article  CAS  PubMed  Google Scholar 

Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: An emerging targeting technique for protein degradation in drug discovery. BioEssays. 2018;40(4):e1700247.

Article  PubMed  Google Scholar 

Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hamman BD, Crews CM. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun. 2019;10(1):131.

Article  PubMed  PubMed Central  Google Scholar 

Lai AC, Crews CM. Induced protein degradation: An emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–14.

Article  CAS  PubMed  Google Scholar 

Xiong Y, Zhong Y, Yim H, Yang X, Park KS, Xie L, Poulikakos PI, Han X, Xiong Y, Chen X, Liu J, Jin J. Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets. J Am Chem Soc. 2022;144(49):22622–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreau K, Coen M, Zhang AX, Pachl F, Castaldi MP, Dahl G, Boyd H, Scott C, Newham P. Proteolysis-targeting chimeras in drug development: A safety perspective. Br J Pharmacol. 2020;177(8):1709–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, Zhang Y, Xing D, Zhang R. PROTACs technology for targeting non-oncoproteins: Advances and perspectives. Bioorg Chem. 2021;114:105109.

Article  CAS  PubMed  Google Scholar 

Koroleva OA, Dutikova YV, Trubnikov AV, Zenov FA, Manasova EV, Shtil AA, Kurkin AV. PROTAC: Targeted drug strategy. Principles and limitations. Russ Chem Bull. 2022;71(11):2310–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao J, Yang L, Lei S, Zhou F, Nie H, Peng B, Xu T, Chen X, Yang X, Sheng C, Rao Y, Pu K, Jin J, Xu Z, Yu H. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Sci Bull (Beijing). 2023;68(10):1069–8485.

Article  CAS  PubMed  Google Scholar 

Chen C, Yang Y, Wang Z, Li H, Dong C, Zhang X. Recent advances in pro-PROTAC development to address on-target off-tumor toxicity. J Med Chem. 2023;66(13):8428–40.

Article  CAS  PubMed  Google Scholar 

Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman KG. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2016;113(26):7124–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (PROTACs) in “beyond rule-of-five” chemical space: Recent progress and future challenges. Bioorg Med Chem Lett. 2019;29(13):1555–64.

Article  CAS  PubMed  Google Scholar 

Matsson P, Kihlberg J. How big is too big for cell permeability? J Med Chem. 2017;60(5):1662–4.

Article  CAS  PubMed  Google Scholar 

Kiely-Collins H, Winter GE, Bernardes GJL. The role of reversible and irreversible covalent chemistry in targeted protein degradation. Cell Chem Biol. 2021;28(7):952–68.

Article  CAS  PubMed  Google Scholar 

Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: A drug metabolism and pharmacokinetics perspective. Drug Discov Today. 2020;25(10):1793–800.

Article  CAS  PubMed  Google Scholar 

Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q. Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation. Chem Soc Rev. 2022;51(13):5330–2350.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeng S, Huang W, Zheng X, Liyan C, Zhang Z, Wang J, Shen Z. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021;210:112981.

Article